Forget the recipes: Let's talk data [2]

Pain Medicine

Volumn 9, Issue 2, 2008, Pages 261-265

  Passik, Steven D ^a   Kirsh, Kenneth L ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL CITRATE; HYDROCODONE; METHADONE; OPIATE; OXYCODONE;

CANCER PAIN; CANCER PATIENT; CANCER SURVIVOR; CHRONIC PAIN; CLINICAL TRIAL; DRUG MISUSE; HIGH RISK PATIENT; HUMAN; LETTER; NARCOTIC DEPENDENCE; OFF LABEL DRUG USE; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; RISK FACTOR; TERMINAL DISEASE;

EID: 39649124910     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2008.00414.x     Document Type: Letter

References (44)

1. Passik SD, Kirsh KL, McDonald MV, et al. A pilot survey of aberrant drug-taking attitudes and behaviors in samples of cancer and AIDS patients. J Pain Symptom Manage 2000;19(4):274-86.
2. Passik SD, Kirsh KL, Whitcomb LA, et al. Monitoring outcomes during long-term opioid therapy for non-cancer pain: Results with the pain assessment and documentation tool. J Opioid Manag 2005;1(5):257-66.
3. Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother 2006;20(2):5-13.
4. Bishop G. Health psychology: Integrating mind and body. Boston: Allyn and Bacon; 1994.
5. Brannon L, Feist J. Health Psychology: An Introduction to Behavior and Health. Boston: Brooks/Cole Publishing; 1997.
6. Passik SD, Dugan W, McDonald M, et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998;16:1594-600.
7. Blot WJ. Alcohol and cancer. Cancer Res 1992;52:S2119-23.
8. Bruera E, Moyano J, Seifert L, et al. The frequency of alcoholism among patients with pain due to terminal cancer. J Pain Symptom Manage 1995;10(8):599.
9. Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer 2007;110(8):1665-76.
10. Smith-Warner SA, Spiegelman D, Yaun S, et al. Alcohol and breast cancer in women: A pooled analysis of cohort studies. J Amer Med Assoc 1998;279:535-40.
11. Grant BF, Dawson DA. Age at onset of alcohol use and its association with DSM-IV alcohol abuse and dependence: Results from the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse Treat 1997;9:103-10.
12. Hingson RW, Heeren T, Winter MR. Age of alcohol-dependence onset: Associations with severity of dependence and seeking treatment. Pediatrics 2006;118:755-63.
13. Volkow ND. What do we know about drug addiction? Am J Psychiatry 2005;162(8):1401-2.
14. Volkow ND, Li TK. Drugs and alcohol: Treating and preventing abuse, addiction and their medical consequences. Pharmacol Ther 2005;108(1):3-17.
15. Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006;83(suppl 1):S4 -7.
16. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. Pain Med 2005;6(6):432-42.
17. Kirsh KL, Passik SD. Palliative care of the terminally ill drug addict. Cancer Invest 2006;24(4):425-31.
18. Passik SD, Theobald DE. Managing addiction in advanced cancer patients: Why bother? J Pain Symptom Manage 2000;19(3):229-34.
19. Hancock CM. OxyContin use and abuse. Clin J Oncol Nurs 2002;6(2):109.
20. Hays L, Kirsh KL, Passik SD. Seeking drug treatment for OxyContin abuse: A chart review of consecutive admissions to a substance abuse treatment facility in the Bluegrass region of Kentucky. J Natl Compr Canc Netw 2003;1(3):423-8.
21. Joranson D, Ryan K, Gilson A, Dahl J. Trends in Medicaid use and abuse of opioid analgesics. JAMA 2000;283:1710-4.
22. Passik SD, Kirsh KL, Donaghy K, Portenoy RK. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 2006;22(2):173-81.
23. Cicero TJ, Surratt H, Inciardi JA, Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf 2007;16(8):827-40.
24. Benowitz NL. Pharmacology of nicotine: Addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996;36:597-613.
25. Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: A biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs 2000;32(suppli - iv):1-112.
26. Breslau N, Johnson EO, Hiripi E, Kessler R. Nicotine dependence in the United States: Prevalence, trends, and smoking persistence. Arch Gen Psychiatry 2001;58(9):810-6.
27. Giovino GA, Henningfield JE, Tomar SL, Escobedo LG, Slade J. Epidemiology of tobacco use and dependence. Epidemiol Rev 1995;17(1):48-65.
28. Lynch BS, Bonnie RJ. Growing up Tobacco Free: Preventing Nicotine Addiction in Children and Youths. Washington, DC: Institute of Medicine, National Academies Press; 1994.
29. Buka SL, Shenassa ED, Niaura R. Elevated risk of tobacco dependence among offspring of mothers who smoked during pregnancy: A 30-year prospective study. Am J Psychiatry 2003;160:1978-84.
30. Carmelli D, Swan GE, Robinette D, Fabsitz R. Genetic influence on smoking-a study of male twins. N Engl J Med 1992;327(12):829-33.
31. Lessov CN, Martin NG, Statham DJ, et al. Defining nicotine dependence for genetic research: Evidence from Australian twins. Psychol Med 2004;34(5):865-79.
32. Sabol SZ, Nelson ML, Fisher C, et al. A genetic association for cigarette smoking behavior. Health Psychol 1999;18(1):7-13.
33. Wright AJ, Weinman J, Marteau TM. The impact of learning of a genetic predisposition to nicotine dependence: An analogue study. Tob Control 2003;12(2):227-30.
34. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007;8(7):573-82.
35. Passik SD. Responding rationally to recent report of abuse/diversion of Oxycontin. J Pain Symptom Manage 2001;21(5):359.
36. Substance Abuse and Mental Health Services Administration. Results from the 2004 National Survey on Drug Use and Health: National Findings. DHHS Pub. No. SMA 05-4062, 2005.
37. Manchikanti L, Manchukonda R, Pampati V, Damron KS. Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving short-acting (hydrocodone) or long-acting (methadone) opioids. Pain Physician 2005;8(3):257-61.
38. Butler SF, Benoit CM, Budman SH, et al. Development and validation of an opioid attractiveness scale: A novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006;3(1):5 [Epub ahead of print].
39. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2004: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-28, DHHS Publication No. (SMA) 06-4143. Rockville, MD, 2006.
40. Cicero TJ, Inciardi JA. Diversion and abuse of methadone prescribed for pain management. JAMA 2005;293(3):297-8.
41. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005;6(10):662-72.
42. Landy SH. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: A case series. Headache 2004;44(8):762-6.
43. Shaiova L, Wallenstein D. Outpatient management of sickle cell pain with chronic opioid pharmacotherapy. J Natl Med Assoc 2004;96(7):984-6.
44. Taylor DR, Webster LR, Chun SY, et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: Patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med 2007;8(3):281-8.